tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Avalo Therapeutics initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Avalo Therapeutics (AVTX) with an Overweight rating and no price target Avalo is a clinical-stage biotech company focused on autoimmune diseases, the analyst tells investors in a research note. The firm says the company’s lead drug AVTX-009 is an IL-1N2 antibody currently in a Phase 2 trial for hidradenitis suppurativa with a readout expected in mid-2026.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1